The Hope Clinic of the Emory Vaccine Center will significantly expand enrollment in a nationwide HIV vaccine trial called HVTN 505, conducted by the NIH-funded HIV Vaccine Trials Network. HVTN 505/LifeForward is the only HIV vaccine efficacy trial currently enrolling anywhere in the world.
The study is expanding from 1,350 to 2,200 participants nationally to allow scientists to evaluate whether the injected vaccine, compared to placebo injections, has a significant effect on reducing the number of new HIV infections. Originally, the study was designed to determine whether the vaccine can lower viral load among those who become HIV-infected, and whether the vaccine continues to be safe.
“Despite advances in health education, behavioral changes and therapies, an HIV vaccine is a critical part of the fight to prevent and stop this challenging global disease,” says Mark Mulligan, MD, executive director of Emory’s Hope Clinic and co-director of the Emory Center for AIDS Research (CFAR) Clinical Core. “We’re very grateful and proud of the volunteers who have joined our study thus far. Developing an effective HIV vaccine requires the participation of many volunteers in every population and around the world.”
To date, Atlanta and the Hope Clinic have enrolled 112 volunteers in this study. If you are an HIV-negative man or a transwoman who has sex with men, and are 18-50 years old, you may qualify for enrollment in this important trial. You cannot get HIV from the vaccine. You can learn more about HVTN 505/LifeForward at www.HopeTakesAction.org.
In addition to Atlanta, HVTN 505 is being tested at research clinics in 20 cities around the country.
The Robert W. Woodruff Health Sciences Center of Emory University is an academic health science and service center focused on missions of teaching, research, health care and public service.